In BRAF mutant and vemurafenib-resistant cells, the combination therapy of romidepsin and interferon-alpha (IFN-α) effectively reduces melanoma invasiveness, induces mixed apoptotic and necroptotic cell death, and reverses resistance to BRAF inhibitors. The gene discussed is BRAF; the disease is melanoma.